Immune checkpoint inhibitors counter the endogenous inactivation or exhaustion of anti-tumor adaptive immunity by cytotoxic CD8+ T cells via blocking the programmed cell death (PD-1) or cytotoxic T lymphocyte-associated antigen-4 (CTLA4) pathways in various tumor types (12, 13). This evidence concerns the gene CD8A and neoplasm.